BiotechTube

REGN7508 + Acetylsalicylic Acid (ASA) + Placebo

Phase 3Recruiting
1 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Symptomatic Venous Thromboembolism (VTE)

Conditions

Symptomatic Venous Thromboembolism (VTE)

Trial Timeline

Nov 24, 2025 → Jul 16, 2027

NCT ID
NCT07213778

About REGN7508 + Acetylsalicylic Acid (ASA) + Placebo

REGN7508 + Acetylsalicylic Acid (ASA) + Placebo is a phase 3 stage product being developed by Regeneron Pharmaceuticals for Symptomatic Venous Thromboembolism (VTE). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07213778. Target conditions include Symptomatic Venous Thromboembolism (VTE).

What happened to similar drugs?

3 of 16 similar drugs in Symptomatic Venous Thromboembolism (VTE) were approved

Approved (3) Terminated (4) Active (9)
❌Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
🔄ISV-305Sun PharmaceuticalPhase 3
🔄rabeprazole sodium + PlaceboEisaiPhase 3
🔄Esomeprazole + Matching placeboAstraZenecaPhase 3
🔄Pasireotide + OctreotideNovartisPhase 3
✅valsartanNovartisApproved
🔄Apixaban + Standard of carePfizerPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07213778Phase 3Recruiting

Competing Products

20 competing products in Symptomatic Venous Thromboembolism (VTE)

See all competitors
ProductCompanyStageHype Score
Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
32
ISV-305Sun PharmaceuticalPhase 3
40
rabeprazole sodium + PlaceboEisaiPhase 3
40
Verinurad + Febuxostat + DapagliflozinAstraZenecaPhase 2
35
RDEA3170 + Febuxostat + BenzbromaroneAstraZenecaPhase 1/2
32
Esomeprazole + Matching placeboAstraZenecaPhase 3
40
DFV890 + PlaceboNovartisPhase 2
35
Omalizumab + Omalizumab + PlaceboNovartisPhase 2
35
Pasireotide + OctreotideNovartisPhase 3
40
TegaserodNovartisPhase 2
35
valsartanNovartisApproved
43
Atorvastatin - Cholestyramine - SitosterolPfizerPre-clinical
26
Epoetin biosimilarPfizerPre-clinical
26
Apixaban + Standard of carePfizerPhase 3
40
Azithromycin plus chloroquinePfizerPhase 3
32
MavacamtenBristol Myers SquibbApproved
50
Aficamten + PlaceboSanofiPhase 3
44
Vandetanib 300 mgSanofiPre-clinical
26
Rivaroxaban + PlaceboBayerPhase 3
37
Droxidopa capsules + Placebo capsulesLundbeckApproved
40